Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-533 in Relapsed/Refractory Multiple Myeloma
NCT05227144Phase 1Completed
- Sponsor
- ORIC Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ORIC-533 in multiple myeloma (MM) (2 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 12 months, Number of participants with adverse events at 36 months and 1 more. Started Jan 2022; status: completed.
02
Drugs
ORIC-533
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05227144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227144.